Physician profile
Faraanak Mobini
NPI 1780910737
$2,691.23
in general payments reported to CMS, 2019-2025
19 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $13.32 · 2023: $633 · 2024: $891 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $190 · Travel and Lodging: $31.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.20 |
| Education | $189.98 |
| Travel and Lodging | $31.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,522.88 | 2021-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $369.93 | 2023-2025 | |
| Noctrix Health, INC. | $169.88 | 2024 | Nidra |
| Insmed, INC. | $134.57 | 2023-2025 | Arikayce |
| Glaxosmithkline, LLC. | $73.34 | 2024-2025 | Nucala |
| Harmony Biosciences LLC | $69.80 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $47.00 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $46.47 | 2023-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $34.74 | 2023 | Lumryz |
| United Therapeutics Corporation | $34.16 | 2023 | Tyvaso |
| Grifols USA, LLC | $31.33 | 2023 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $27.64 | 2023 | Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.76 | 2023 | Ofev |
| Axsome Therapeutics, INC. | $20.26 | 2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.87 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.47 | 2023 | Breztri |
| Resmed Corp | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraanak Mobini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.